Correct Answer: C. PTEN
Cowden syndrome is an autosomal dominant hereditary cancer syndrome caused by loss-of-function mutations in the PTEN gene (phosphatase and tensin homolog), located on chromosome 10q23. PTEN is a tumour suppressor that negatively regulates the PI3K/Akt signalling pathway—a critical pathway controlling cell proliferation, survival, and apoptosis. Loss of PTEN function leads to unopposed Akt activation, resulting in increased cell survival and proliferation. Clinically, Cowden syndrome presents with multiple hamartomas affecting the gastrointestinal tract (polyps, particularly in the colon and small bowel), breast, thyroid, and skin (trichilemmomas, acanthosis nigricans-like lesions). Patients have a significantly elevated lifetime risk of breast cancer (50%), thyroid cancer (10%), and colorectal cancer. The diagnosis is clinical (Lhermitte–Duclos disease—cerebellar hamartomas—is pathognomonic) and confirmed by PTEN mutation testing. Indian guidelines recommend surveillance colonoscopy and breast imaging in affected families, particularly in high-risk populations with consanguinity.
Why the other options are wrong
A. Ras — Ras mutations are associated with sporadic colorectal cancer and various solid tumours (pancreatic, lung), but NOT with Cowden syndrome. Ras is an oncogene (gain-of-function), whereas Cowden syndrome results from a tumour suppressor gene loss. This is a common trap—students may confuse hereditary cancer syndromes with oncogenic mutations. B. WT1 — WT1 (Wilms tumour suppressor) mutations cause Wilms tumour in children and WAGR syndrome (Wilms, Aniridia, GU anomalies, Retardation). It is NOT associated with Cowden syndrome or the hamartoma-polyp phenotype. This option tests whether students can distinguish between different hereditary cancer syndromes. D. p53 — p53 mutations cause Li–Fraumeni syndrome, characterized by early-onset breast cancer, sarcomas, brain tumours, and adrenocortical carcinoma—NOT hamartomatous polyps or the Cowden phenotype. While both are tumour suppressors, their clinical presentations and target tissues are distinct.
High-Yield Facts
- PTEN mutation is the pathognomonic genetic defect in Cowden syndrome (autosomal dominant, chromosome 10q23).
- Lhermitte–Duclos disease (cerebellar hamartomas) is the hallmark CNS manifestation of Cowden syndrome.
- Breast cancer risk in Cowden syndrome is ~50% lifetime; thyroid and colorectal cancers also significantly elevated.
- PTEN loss leads to unopposed PI3K/Akt signalling, driving cell survival and proliferation.
- Trichilemmomas (benign skin tumours) and acanthosis nigricans-like lesions are characteristic cutaneous features.
- Cowden syndrome requires surveillance colonoscopy and breast imaging per Indian cancer genetics guidelines.
Mnemonics
PTEN in Cowden Phosphatase Tensin homolog loss → Excess cell growth → Neoplasia (hamartomas + cancers). PTEN is the 'brake' on PI3K/Akt; lose it, and cells proliferate unchecked. Cowden = Hamartoma Syndrome Cowden = Cerebellar hamartomas (Lhermitte–Duclos) + Colon polyps + Cancer risk. Remember: multiple hamartomas across organs = think PTEN.
NBE Trap
NBE pairs Cowden syndrome with other hereditary cancer syndromes (Li–Fraumeni with p53, Wilms with WT1) to test whether students can match the specific gene to the specific clinical phenotype. The hamartoma-polyp presentation is the discriminating clue for PTEN.
Clinical Pearl
In Indian clinical practice, Cowden syndrome is often underdiagnosed because trichilemmomas and GI polyps are attributed to sporadic causes. A family history of early breast cancer + cerebellar hamartomas on imaging should prompt PTEN testing—early identification allows surveillance and risk reduction in relatives, particularly important in consanguineous Indian families.
_Reference: Robbins Ch. 7 (Genetic Disorders); Harrison Ch. 87 (Hereditary Cancer Syndromes)_